『Beta Finch - Merck - MRK - EN』のカバーアート

Beta Finch - Merck - MRK - EN

Beta Finch - Merck - MRK - EN

著者： Beta Finch
無料で聴く

AI-powered earnings call analysis for Merck (MRK). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Merck Q2 2026 Earnings Analysis

    Merck Q2 2026 Earnings Analysis
    2026/08/29
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    Welcome to Beta Finch, your AI-powered earnings breakdown for the news that's moving your portfolio.

    ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan as always, and today we're digging into Merck's second quarter 2026 numbers. Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good disclaimer to lead with, because there's a lot to unpack here — this was a noisy quarter on paper but honestly a pretty exciting one underneath the hood.

    ALEX: Right, let's start with the headline numbers. Merck posted revenue of $16.6 billion, up 5%, or 4% if you strip out currency effects. Oncology and animal health carried a lot of that weight, plus growing contributions from newer launches.

    JORDAN: But here's where it gets interesting — on the bottom line, Merck actually reported a loss of $0.13 per share. That sounds alarming until you realize it's almost entirely a one-time accounting quirk.

    ALEX: Exactly. They completed the acquisition of Terns Pharmaceuticals this quarter, picking up a promising CML — chronic myeloid leukemia — drug candidate. That came with a $5.7 billion charge, and because it wasn't tax-deductible, their tax rate for the quarter ballooned to over 160%.

    JORDAN: Which tanked EPS by $2.31 a share. Take that out, and the underlying business is actually performing quite well. It's a classic case of "read past the GAAP headline number."

    ALEX: They also raised and narrowed full-year guidance — now expecting revenue between $66.3 and $67.3 billion, 2-4% growth, and full-year EPS of $2.66 to $2.76.

    JORDAN: Let's talk product performance, because this is really a story of "old reliable" versus "new and exciting." KEYTRUDA, the flagship cancer immunotherapy, grew 4% to $8.4 billion — still the workhorse, but management flagged that U.S. growth is moderating as it approaches peak penetration in a lot of indications.

    ALEX: Meanwhile the newer stuff is popping. WINREVAIR, their pulmonary hypertension drug, was up 75% to $588 million. WELIREG jumped 67%. CAPVAXIVE, their pneumococcal vaccine, up 40%.

    JORDAN: Those growth rates matter a lot for the bigger narrative here, which is what happens when KEYTRUDA eventually loses patent exclusivity around the end of the decade. CEO Rob Davis addressed this directly in the Q&A — he called it "more of a hill than a cliff," with a shallow dip and a fast return to growth, backed by more than $70 billion in commercial opportunity from over 20 new products.

    ALEX: And a big one this quarter was LIPFENDRA — the first oral PCSK9 inhibitor approved by the FDA, for lowering LDL cholesterol. It got fast-tracked through a national priority voucher process.

    JORDAN: This is a big deal because current injectable PCSK9 drugs only reach about 5% of the eligible market — mostly because doctors and patients don't love needles for a chronic condition. An oral pill could meaningfully expand that market. Davis was clear they're not trying to steal share from injectables, they're trying to grow the whole pie — 30 million Americans are on lipid therapy but not hitting their LDL targets.

    ALEX: There's also real pipeline momentum beyond LIPFENDRA. Sac-TMT, their Trop-2 antibody-drug conjugate for cancer, put up positive Phase III results in endometrial cancer — ahead of schedule. Same with tulisokibart, their ulcerative colitis drug, which hit positive Phase III results faster than expected too.

    JORDAN: Dr. Dean Li, their research chief, made a point of saying their confidence is actually higher now than it was back in January, because so many of these pipeline bets are reading out early and positive. That's not something yo

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Merck Q1 2026 Earnings Analysis

    Merck Q1 2026 Earnings Analysis
    2026/04/30
    # Beta Finch Podcast Script: Merck Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack here.

    **JORDAN:** That's right, Alex. And before we jump in, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **ALEX:** Thanks, Jordan. Now, let's talk about the headline numbers. Merck reported revenue of $16.3 billion for Q1, which represents 5% growth year-over-year, or 3% excluding foreign exchange impacts. But here's the kicker - they actually posted a loss of $1.28 per share.

    **JORDAN:** Right, and that loss is entirely due to a massive one-time charge. Merck took a $9 billion hit related to their acquisition of Cidara Therapeutics. Without that charge, they would have been profitable. In fact, they raised their full-year guidance, which tells you management feels pretty good about the underlying business.

    **ALEX:** Exactly. They bumped up their revenue guidance to between $65.8 billion and $67 billion for the full year, and raised their EPS guidance to $5.04 to $5.16. But Jordan, let's talk about what's really driving this growth - because it's not just KEYTRUDA anymore.

    **JORDAN:** That's the big story here, Alex. Yes, KEYTRUDA sales were still strong at $8 billion, up 8%, but what caught my attention was how diversified their growth drivers are becoming. WINREVAIR, their pulmonary arterial hypertension drug, hit $525 million in sales. That's a relatively new product showing real traction.

    **ALEX:** And then there's WELIREG, their oral HIF-2-alpha inhibitor, which saw 43% growth to $199 million. Management highlighted they have over 20 new products launching with what they called "blockbuster potential." CEO Rob Davis mentioned a potential commercial opportunity of over $70 billion by the mid-2030s from these new growth drivers alone.

    **JORDAN:** Those are big numbers, Alex. But let's talk about some challenges too. GARDASIL sales dropped 22% to $1.1 billion, mainly due to lower demand in China and Japan. And their new RSV prevention drug ENFLONSIA had minimal sales in Q1, though that was expected due to seasonality.

    **ALEX:** True, but management seemed confident about the RSV product ramping up in the second half of the year. What really stood out to me from the call was their focus on AI and partnerships. They announced a multi-year deal with Google Cloud for AI capabilities, plus expanded collaborations with Tempus AI and the Mayo Clinic.

    **JORDAN:** That's a smart move, especially in drug development where AI could potentially accelerate research timelines. Speaking of their pipeline, they had some interesting updates. The FDA approved their HIV drug IDVYNSO, and they're expecting several priority reviews in the coming months for cancer treatments.

    **ALEX:** The pipeline discussion was fascinating. Dr. Dean Li, their research chief, mentioned they have 17 Phase III studies ongoing for their antibody-drug conjugate sac-TMT, with 13 of those in "first mover" indications. That could be huge if those trials are successful.

    **JORDAN:** And let's not forget the Terns Pharmaceutical acquisition they're working on. They're paying about $5.8 billion for TERN-701, a chronic myeloid leukemia drug candidate. Management thinks it has "multibillion-dollar commercial potential."

    **ALEX:** During the Q&A, analysts were clearly focused on the pipeline readouts coming this year. There was a lot of discussion about their ophthalmology programs and cancer combination therapies. One thing that struck me was how confident management sounded about their diversification strategy.

    **JORDAN:** Absolutely. CFO Caroline Litchfield mentioned

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Merck Q4 2025 Earnings Analysis

    Merck Q4 2025 Earnings Analysis
    2026/02/22
    **BETA FINCH PODCAST SCRIPT - MERCK Q4 2025 EARNINGS**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into Merck's Q4 2025 earnings - and folks, this one's got some really interesting moving parts.

    **ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely. Now Alex, let's start with the headline numbers because Merck delivered some solid, if not spectacular, results.

    **ALEX:** Right, so Q4 revenue came in at $16.4 billion - that's 5% growth year-over-year, or 4% if you strip out foreign exchange impacts. But what's really interesting here is the story behind these numbers.

    **JORDAN:** Exactly. Keytruda, their blockbuster cancer drug, continues to be the workhorse with $8.4 billion in sales, up 5%. But here's what caught my attention - CEO Rob Davis mentioned they now see a path to over $70 billion in potential commercial opportunity by the mid-2030s. That's $20 billion more than just a year ago!

    **ALEX:** That's a massive increase in their pipeline projections. And Jordan, this gets to the heart of what investors are really worried about with Merck - what happens when Keytruda loses patent protection?

    **JORDAN:** Bingo. The so-called "patent cliff." But here's where it gets interesting - Davis dropped some news about potentially extending Keytruda's protection. They have additional patents that could push the loss of exclusivity from December 2028 out to May or even November 2029.

    **ALEX:** That's huge if it holds up. An extra year of Keytruda exclusivity could be worth billions. But let's talk about some of the challenges they're facing. Gardasil, their HPV vaccine, saw sales drop 35% to $1 billion, largely due to lower demand in China and Japan.

    **JORDAN:** Yeah, that's a significant headwind. And looking at their 2026 guidance, they're projecting pretty modest growth - just 1% to 3% revenue growth to between $65.5 and $67 billion. That includes dealing with about $2.5 billion in headwinds from generic competition and pricing pressures.

    **ALEX:** Speaking of 2026, there's this massive one-time charge of about $9 billion related to their acquisition of Sidera Therapeutics. This deal is all about MK1406, a potentially first-in-class flu prevention drug.

    **JORDAN:** This acquisition really stood out to me. Management thinks MK1406 has greater than $5 billion in revenue potential. It's designed as a long-acting antiviral that could prevent influenza in high-risk individuals - basically a once-per-season shot instead of the traditional annual flu vaccine approach.

    **ALEX:** The timing is interesting too, given we're in the middle of what seems to be a pretty severe flu season. Dr. Dean Li, their R&D chief, mentioned they've completed enrollment in the Northern Hemisphere for their Phase 3 trial and are now enrolling patients in the Southern Hemisphere.

    **JORDAN:** Let's pivot to some of their other growth drivers. Winrevair, their pulmonary arterial hypertension drug, continues to impress with $467 million in global sales. They had over 1,500 new patients start treatment in the U.S. alone this quarter.

    **ALEX:** And they just launched Ohtuvayre for COPD after acquiring Verona Pharma. That brought in $178 million in just part of the quarter. These respiratory drugs are clearly becoming a key growth pillar for Merck post-Keytruda.

    **JORDAN:** What I found fascinating in the Q&A was the discussion around their HIV programs. They have this two-drug combination that showed non-inferior results to the standard three-drug regimen. Dr. Li was particularly excited abou

    This episode includes AI-generated content.
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません